Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Takashi Kojima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6346-4588; OpenAlex author ID A5063600818. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 13

  1. The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation. Co-author DOI 10.3390/cancers17091469↗
  2. Gap junction beta-4 accelerates cell cycle progression and metastasis through MET-AKT activation in pancreatic cancer. Co-author DOI 10.1111/cas.16101↗
  3. Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. Last author DOI 10.1007/s00418-019-01821-4↗
  4. Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001485↗
  5. Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. Co-author DOI 10.1038/srep33582↗
  6. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Last author DOI 10.1002/prp2.196↗
  7. c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model. Last author DOI 10.1007/s00418-014-1300-4↗
  8. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. First author DOI 10.1093/carcin/bgt057↗
  9. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. Co-author DOI 10.1136/jclinpath-2011-200400↗
  10. Targeting claudin-4 in human pancreatic cancer. Co-author DOI 10.1517/14728222.2012.708340↗
  11. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. First author DOI 10.1002/jcb.23095↗
  12. Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4. First author DOI 10.1007/s00441-011-1287-2↗
  13. Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2011.06.020↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takumi Konno · 6 shared papers, 2015–2025 · strength 0.73
  2. Daisuke Kyuno · 9 shared papers, 2011–2025 · strength 0.64
  3. Masafumi Imamura · 6 shared papers, 2011–2025 · strength 0.54
  4. Yasutoshi Kimura · 6 shared papers, 2011–2025 · strength 0.54
  5. Akira Takasawa · 7 shared papers, 2011–2025 · strength 0.42
  6. Norimasa Sawada · 9 shared papers, 2011–2016 · strength 0.35
  7. Makoto Osanai · 2 shared papers, 2016–2025 · strength 0.28
  8. Takuro Kyuno · 2 shared papers, 2020 · strength 0.22
  9. Ichiro Takemasa · 2 shared papers, 2020 · strength 0.22
  10. Koichi Hirata · 6 shared papers, 2011–2016 · strength 0.21
  11. Kohichi Takada · 1 shared paper, 2024 · strength 0.19
  12. Tomohiro Kubo · 1 shared paper, 2024 · strength 0.19
  13. Joji Muramatsu · 1 shared paper, 2024 · strength 0.19
  14. Masayoshi Kobune · 1 shared paper, 2024 · strength 0.19
  15. Makoto Yoshida · 1 shared paper, 2024 · strength 0.19
  16. Tatsuya Ito · 5 shared papers, 2011–2015 · strength 0.15
  17. Tsuyoshi Kono · 2 shared papers, 2015–2016 · strength 0.10
  18. Ylermi Soini · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.